

Date: November 16, 2022

**RE: Meeting of the shareholders of ImmunoPrecise Antibodies Ltd. to be held on December 13th (the “Meeting”)**

I, Brad McConn, the Chief Financial Officer of ImmunoPrecise Antibodies Ltd. hereby certify that:

- (a) arrangements have been made to have proxy related materials for the Meeting sent in compliance with National Instrument 54-101 (the “Instrument”), to all beneficial owners at least 21 days before the date fixed for the Meeting;
- (b) arrangements have been made to carry out all of the requirements of the Instrument in addition to those described in subparagraph (a) and
- (c) ImmunoPrecise Antibodies Ltd. is relying on section 2.20 of the Instrument to abridge the time prescribed in subsection 2.5(1) of the Instrument.

*(s) Brad McConn*

---

Name: Brad McConn  
Title: Chief Financial Officer

**Global HQ**

4837 Amber Valley  
Parkway, Suite 11  
Fargo, ND 58104, USA  
+1 (701) 353-0022

**USA – Cambridge**

One Broadway,  
14th Floor  
Cambridge, MA  
02142, USA

**Canada**

3204-4464 Markham St.  
Victoria BC, V8Z 7X8,  
Canada  
+1 (250) 483-0308

**Europe – Oss**

Pivot Park – Building OP  
Kloosterstraat 9  
5349 AB Oss,  
The Netherlands  
+31 412 846 000

**Europe – Utrecht**

Yalelaan 62  
3584 CM Utrecht,  
The Netherlands  
+31 85 016 0916

**Europe – Belgium**

Agoralaan Abis  
3590 Diepenbeek,  
Belgium  
+32 11 286 900